Physician profile
Beth Stein
NPI 1710146865
$87,453.76
in general payments reported to CMS, 2019-2025
16 companies · $55K in 2025
The $55K reported for 2025 was more than what 94% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.73 · 2020: $23.19 · 2021: $46.32 · 2022: $10K · 2023: $8,146 · 2024: $14K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Consulting Fee: $30K · Travel and Lodging: $8,036 · Food and Beverage: $1,682 · Education: $70.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,513.50 |
| Consulting Fee | $29,802.50 |
| Travel and Lodging | $8,036.38 |
| Food and Beverage | $1,682.48 |
| Education | $70.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $59,143.92 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $14,494.98 | 2024-2025 | Rystiggo, Zilbrysq |
| Janssen Biotech, INC. | $6,858.18 | 2025 | |
| Amgen INC. | $4,112.72 | 2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $2,627.78 | 2023-2025 | Ultomiris |
| Grifols USA, LLC | $52.53 | 2022 | |
| Xeris Pharmaceuticals, INC. | $28.72 | 2023 | Keveyis |
| Csl Behring | $23.19 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.07 | 2021 | |
| Abbvie INC. | $16.64 | 2023 | Ubrelvy, Qulipta |
| Sk Life Science, INC. | $14.91 | 2021 | |
| Eisai INC. | $14.56 | 2022 | |
| Mallinckrodt Enterprises LLC | $12.73 | 2019 | |
| Genentech USA, INC. | $12.47 | 2022 | |
| Biogen, INC. | $11.34 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $9.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.